EGFR and lung carcinoma: KRAS mutated lung cancer have been linked with incremented glycolytic flux (95) and this is also the case also for EGFR mutant tumors, in which the activation of PIP3K/AKT/mTORC1 supports glycolysis and consequently fosters cell proliferation (96).